EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieKlinische Studie (Phase II)

Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

Brian M Wolpin, Wungki Park iD, Ignacio Garrido-Laguna, Alexander Spira, Alexander Starodub, David Sommerhalder, Salman R Punekar, Minal Barve, Meredith Pelster, Benjamin Herzberg, Nilofer S Azad, Joel Randolph Hecht und 9 weitere

New England Journal of Medicine · 07.05.2026 · 394 (18) · 1790-1802

DOI: 10.1056/nejmoa2505783 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 07.05.2026. Verfasst von Brian M Wolpin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Piperazines. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Revolution Medicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsPiperazinesras ProteinsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedGenes, rasMutationProgression-Free SurvivalAdministration, OralTime Factors

Substanzen

Antineoplastic AgentsdaraxonrasibPiperazinesras Proteins

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston.
  • Memorial Sloan Kettering Cancer Center, New York.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City.
  • NEXT Oncology Virgina, Virgina Cancer Specialists Research Institute, Fairfax.
  • Christ Hospital, Cincinnati.
  • NEXT Oncology, San Antonio, TX.

ORCID-Profile: Wungki Park

Förderung

  • Revolution Medicines

Zitieren

APA

Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., Azad, N. S., Hecht, J. R., Ou, S. H. I., Lin, T., Kar, S., Tao, L., Vora, R., Hegde, A., Aung, K., …, & RMC-6236-001 Investigators (2026). Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer. New England Journal of Medicine, 394(18), 1790-1802. https://doi.org/10.1056/nejmoa2505783

Vancouver

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer. New England Journal of Medicine. 2026;394(18):1790-1802. doi:10.1056/nejmoa2505783

BibTeX
@article{Wolpin2026,
  author = {Wolpin, Brian M and Park, Wungki and Garrido-Laguna, Ignacio and Spira, Alexander and Starodub, Alexander and Sommerhalder, David and Punekar, Salman R and Barve, Minal and Pelster, Meredith and Herzberg, Benjamin and Azad, Nilofer S and Hecht, Joel Randolph and Ou, Sai Hong Ignatius and Lin, Tong and Kar, Sumit and Tao, Lin and Vora, Rashmi and Hegde, Aparna and Aung, Kyaw and Hong, David S and RMC-6236-001 Investigators, RMC-6236-001 Investigators},
  title = {Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {18},
  pages = {1790--1802},
  doi = {10.1056/nejmoa2505783}
}
Kostenlos starten →